KOAH Akut Alevlenmesine Yaklaşım

Authors

Yenal Karakoç

Synopsis

Acute exacerbation of chronic obstructive pulmonary disease (COPD) is a sudden worsening of symptoms that negatively impacts patient health, increasing hospital admissions and mortality rates. Exacerbations are classified into mild, moderate, and severe categories based on treatment requirements and severity. Infections account for nearly 70% of exacerbations, with viral infections triggering the most severe attacks that lead to deeper hypoxemia and prolonged hospital stays. Diagnosis involves assessing oxygen saturation, chest X-rays, complete blood count, biochemistry, and arterial blood gas when respiratory failure is suspected. Hospitalization criteria include severe resting dyspnea, acute respiratory failure, new physical signs, and inadequate response to initial therapy. Pharmacological management centers on short-acting bronchodilators (preferably via nebulizers), systemic corticosteroids (40 mg daily prednisolone for 5 days), and targeted antibiotics when purulent sputum indicates bacterial infection. Oxygen therapy aims to maintain saturation levels between 88% and 92%. Non-invasive mechanical ventilation (NIV) serves as the primary ventilatory support for acute respiratory failure, whereas invasive mechanical ventilation is reserved for cases where NIV fails, is not tolerated, or severe contraindications exist.

References

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095- 128

Wedzicha JA, Seemungal TA. COPD exacerbations: Defining their cause and prevention. Lancet 2007; 370: 786-96.

Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65

Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-13

Pozo-Rodriguez F, Lopez-Campos JL, Alvarez-Martinez CJ, et al. Clinical audit of COPD patients requiring hospital admission in Spain: AUDIPOC study. PLoS One 2012; 7: e42156

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease: 2018 Report. http://www.goldcopd.org

Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006; 61: 250-8.

Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355.

Mohan A, Chandra S, Agarwal D, et al. Pandey RM. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010; 15: 536-42.

Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-21.

Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007 (6):1224-38.

Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693.

Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 19;12:CD005074.

Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008 Jan;133(1):34-41.

Walters JA, Tan DJ, White CJ, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Sep 1;(9):CD001288.

Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017:15;49(3).

de Jong YP, Uil SM, Grotjohan HP, et al. Oral or IV prednisolone in the treatment of COPD exacerbations: A randomized,controlled, double-blind study. Chest. 2007 Dec;132(6):1741-7.

Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010257.

Clark TW, Medina MJ, Batham S, et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J. 2015 Jan;45(1):76-86.

Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 12:CD010257.

Lin SM, Liu KX, Lin ZH, Lin PH. Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systematic review and meta-analysis. Respir Med. 2017 Oct;131:58-64.

Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvazive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med. 2012 Jan 15;185(2):152-9.

Published

May 20, 2021

License

License